Compare ESRT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | DSGN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.0M | 819.6M |
| IPO Year | 2012 | 2021 |
| Metric | ESRT | DSGN |
|---|---|---|
| Price | $5.22 | $12.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.35 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 2.5M | 798.4K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $768,270,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | $521.50 | ★ N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $4.87 | $3.33 |
| 52 Week High | $8.39 | $17.25 |
| Indicator | ESRT | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 58.93 |
| Support Level | $4.87 | $9.78 |
| Resistance Level | $5.83 | $13.54 |
| Average True Range (ATR) | 0.21 | 0.63 |
| MACD | -0.04 | 0.25 |
| Stochastic Oscillator | 15.28 | 91.46 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.